x

Coronavirus

BioNTech Says It Plans 2 Billion Vaccine Doses

January 11, 2021

Germany’s BioNTech, which developed the first COVID-19 vaccination on the market with American partner Pfizer, says it expects to produce 2 billion doses in 2021 with ramped-up manufacturing.

Company CEO and co-founder Ugur Sahin says with three manufacturing sites in the United States and three in Europe operating or coming online soon, it expects to approximately double the number of doses committed for this fiscal year.

The company said in a presentation Monday to the annual J.P. Morgan Healthcare Conference that it is also looking to expand the people able to receive its vaccine to include pregnant women and children, among others.

As of Jan 10, the company says it has already shipped 32.9 million doses of its vaccine. The vaccine was 95% effective in trials.

The company’s vaccine currently has to be stored at extremely cold temperatures, making delivery to remote areas difficult. But the company says it’s working on a more stable version.

RELATED

ATHENS – While the New Democracy government is easing health restrictions for rabid anti-vaxxers, those fully vaccinated against COVID-19 may need a fourth shot in the autumn.

Top Stories

Columnists

A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.

Video

Greek-American Cornell Student Rescues Man on Subway Tracks in the Bronx

NEW YORK – Greek-American Cornell University senior Bryce Demopoulos rescued a man who had fallen on the subway tracks at the Third Avenue-138 Street station on the No.

Enter your email address to subscribe

Provide your email address to subscribe. For e.g. abc@xyz.com

You may unsubscribe at any time using the link in our newsletter.